H ypertension is estimated to affect 46% of the US adult population. 1 It increases the risk of developing heart disease, stroke, and kidney disease, which are leading causes of death.
2 A large number of hypertensive patients, especially blacks, exhibit increased blood pressure (BP) salt-sensitivity. [3] [4] [5] [6] MicroRNAs are small, highly conserved, noncoding RNAs that regulate the level of their target proteins by translational repression or mRNA degradation, [7] [8] [9] [10] and the effects of several microRNAs in kidney disease have been reported. [11] [12] [13] [14] [15] [16] The role of miR-192, in particular, has been studied extensively in the renal glomeruli, where it contributes to glomerular sclerosis found in diabetic nephropathy. [17] [18] [19] [20] However, much less is known about the role renal microRNAs play in hypertension. It has been reported that hsa-miR-181a and hsa-miR-663 levels are lower in hypertensive kidneys and could contribute to upregulation of renin expression. 21 Renal miR-214-3p contributes to hypertension in rats and possibly in humans, which is mediated, at least in part, by targeting eNOS (endothelial nitric oxide synthase) directly. 22 We showed previously that miR-192-5p was one of the most abundant microRNAs in the kidney. 23 In addition, we have shown that the level of miR-192-5p is 20-fold higher in the proximal tubules than in the glomeruli, and miR-192-5p targets the mRNA of the β1 subunit of the Na + /K + -ATPase (ATP1B1) through its unexpected complementarity with a sequence in the 5' instead of the 3' untranslated region. 24 The Na + /K + -ATPase drives renal tubular reabsorption of sodium and, secondarily, many other substances. Reduction of miR-192-5p blunts the adaptive increase of urine output in mice fed a high-salt diet. 24 Small microRNA deep sequencing analysis of human kidney biopsy specimens has demonstrated lower levels of miR-192-5p in patients with hypertensive nephrosclerosis. 22 However, the functional role of miR-192 in the development of hypertension remains unknown.
In the present study, we identified lower levels of miR-192-5p in kidney biopsy specimens from patients with hypertension in addition to patients with hypertensive nephrosclerosis. Subsequently, we performed studies in a rat model of hypertension and a Mir192 knockout mouse model with the Abstract-MicroRNA miR-192-5p is one of the most abundant microRNAs in the kidney and targets the mRNA for ATP1B1 (β1 subunit of Na + /K + -ATPase). Na + /K + -ATPase drives renal tubular reabsorption. We hypothesized that miR-192-5p in the kidney would protect against the development of hypertension. We found miR-192-5p levels were significantly lower in kidney biopsy specimens from patients with hypertension (n=8) or hypertensive nephrosclerosis (n=32) compared with levels in controls (n=10). Similarly, Dahl salt-sensitive (SS) rats showed a reduced abundance of miR-192-5p in the renal cortex compared with congenic SS.13 BN26 rats that had reduced salt sensitivity (n=9; P<0.05). Treatment with anti-miR-192-5p delivered through renal artery injection in uninephrectomized SS.13 BN26 rats exacerbated hypertension significantly. Mean arterial pressure on a 4% NaCl high-salt diet at day 14 post anti-miR-192-5p treatment was 16 mm Hg higher than in rats treated with scrambled anti-miR (n=8 and 6; P<0.05). Similarly, Mir192 knockout mice on the high-salt diet treated with Ang II (angiotensin II) for 14 days exhibited a mean arterial pressure 22 
Methods
The data that support the findings of the present study are available from the corresponding author on reasonable request.
Human Kidney Biopsy Samples
Protocols involving the use of human materials and information were approved by and performed at Shanghai Jiao Tong University Affiliated Sixth People's Hospital. Records in the pathological archive at the hospital were searched to identify subjects diagnosed with hypertensive nephrosclerosis without any other type of renal injury, hypertensive subjects diagnosed with minimal or no renal injury, and normotensive subjects with minimal or no renal injury, as described previously. 22 Kidney biopsy blocks were cut into 10 µm sections, and total RNA was extracted from three sections of each subject using the miRNeasy FFPE kit (Qiagen, Germantown, MD) as described previously.
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Animal Models
The Institutional Animal Care and Use Committee at the Medical College of Wisconsin approved all animal protocols used in the present study. All animals were housed in an American Association for Accreditation of Laboratory Animal Care-accredited animal care facility at the Medical College of Wisconsin with free access to food and water. Male Dahl salt-sensitive (SS) and congenic SS.13 BN26 (L26) rats were generated as described previously. 26, 27 All animals were fed a custom AIN-76A purified rodent chow (0.4% NaCl, Purified AIN-76; Dyets, Bethlehem, PA) after weaning. Expression experiments were performed in 18 rats per strain placed on a lower-salt (LS) diet containing 0.4% NaCl at weaning and kept on this diet until they were 6 weeks old. At that time, half of the rats from each strain were switched to a high-salt (HS) diet of 4.0% NaCl for a week. At the end of the seventh week of life, tissues were collected from all rats. The male rats in experiments that used renal artery injections were 10 weeks old. Mir192 knockout mice of the 129S1/SvlmJ background were bred inhouse from homozygous breeder pairs obtained initially from Beckman Research Institute of City of Hope. 19 Mice of the background 129S1/ SvlmJ strain were obtained from Jackson Laboratories (Bar Harbor, ME) and used as wild-type (WT) controls. The knockout and WT mice were on the same diet and maintained in the same environment at the Medical College of Wisconsin for at least 1 week before surgical preparation and 2 weeks before baseline measurements were started.
BP Monitoring
BP monitoring was performed using DSI PA-C40, HD-S10, or DSI TA11PA-C10 transmitter devices implanted in the rats or mice as per the manufacturer's instructions. Telemeters were implanted into the carotid artery of both rats and mice. After a 7-day recovery period, BP data were collected and analyzed using Dataquest A.R.T. 4.31 software (Data Sciences International, St. Paul, MN).
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Right Nephrectomy
Animals were anesthetized. An incision was made in the right flank to expose the right kidney. A suture was tied at the hilum to prevent bleeding, the kidney was removed and the incision sutured.
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Renal Artery Injection
Animals were anesthetized. An incision was made in the left inguinal area to expose and isolate the left femoral artery. A stretched P10 catheter prefilled with saline was inserted and advanced into the aorta to the level of the left renal artery. A midline incision was made to reveal the left kidney and renal artery. The catheter was guided into the left renal artery with the aid of forceps and advanced from the femoral end. The renal vein was clamped with an aneurysm clip at the renal hilum immediately before injection of locked nucleic acid oligonucleotides. Ultrasound was applied to the kidney at 1 MHz and 10% power for 60 s after the injection. The clamp was removed, and the catheter pulled out from the femoral end where the femoral artery was tied, after which the femoral and the abdominal incisions were sutured.
Locked Nucleic Acid-Modified Anti-miR
A scrambled anti-miR or anti-miR-192-5p oligonucleotides from Exiqon (Woburn, MA) were injected through the left renal artery of 10-to 11-week-old SS.13 BN26 rats at a dose of 2 mg/kg body weight. We reported previously that anti-miRs were effective when administered systemically (intravenously or intraperitoneally) at the dose of 10 mg/kg. 24, 34 We used 20% of the systemic dose for intrarenal artery administration in the present study. Tissues were collected 3 to 5 days later for quantitative polymerase chain reaction (PCR) quantification of miR-192-5p or 2 weeks after the injection when BP measurements via radiofrequency telemetry were completed.
Locked Nucleic Acid-Modified GapmeR
GapmeR that targeted Atp1b1 or control scrambled GapmeR from Exiqon was injected through the left renal artery of 10-to 11-weekold SS.13 BN26 rats at a dose of 5 mg/kg body weight. Preliminary experiments performed in 17 Sprague-Dawley rats and 6 SS rats indicated the GapmeR was efficient for knocking down ATP1B1 in the renal cortex at the dose of 5 mg/kg, but not 1 or 2 mg/kg.
Real-Time Reverse Transcription PCR
RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA). 35 TaqMan MicroRNA Assays and CYBR Green Chemistry were used in an Applied Biosystems real-time PCR instrument as described previously.
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Western Blot
Proteins were extracted from renal cortex samples using the Mem-PER Plus Membrane Protein Extraction Kit from Thermo Fisher Scientific (Waltham, MA). A monoclonal antibody for ATP1B1 from Thermo Fisher Scientific (MA1-16732) was used at a 1:2500 dilution. Coomassie Blue staining was used to normalize protein loading as described previously. 34, 35 A Bio-Rad Criterion 10% Tris-HCl gel was used to analyze the 50 kDa target protein. 
Statistical Analysis
Data were expressed as means±SEM and analyzed for significance using the Students t test for comparisons between 2 groups. A 2-way ANOVA followed by multiple comparisons with the Holm-Sidak test was used for comparisons between multiple groups. Two-way repeated measures ANOVA was used to analyze data obtained on consecutive days. P<0.05 was considered significant.
Results
miR-192-5p Levels Are Lower in Kidney Biopsies From Patients With Hypertension or Hypertensive Nephrosclerosis
The level of miR-192-5p in kidney biopsy specimens from patients with hypertension but no overt renal histological abnormalities (n=8) was 45% of the level in control subjects (n=10; P<0.05). The level of miR-192-5p in hypertensive nephrosclerosis without any other type of kidney disease (n=32) was 52% of the control (P<0.05; Figure 1 ). Clinical characteristics of these patients were described previously and reproduced in Table S1 in the online-only Data Supplement with permission. The 3 groups of patients had similar age and sex distributions. Estimated glomerular filtration rate tended to be lower in the hypertensive nephrosclerosis group than in the other 2 groups, but the difference was not statistically significant. The hypertension and hypertensive nephrosclerosis groups which had higher BP than did the controls were treated with ≥1 antihypertensive medications and included subjects with diabetes mellitus. miR-192-5p remained significantly lower in the hypertension and hypertensive nephrosclerosis groups compared with the controls after the diabetic subjects were removed from the analysis. We did not have sufficient data to test the effect of the medications.
Intrarenal Knockdown of miR-192-5p Exacerbates Hypertension in SS.13 BN26 Rats
The Dahl SS rat is the polygenic, hereditary model of human SS hypertension used most commonly. 38, 39 The SS.13 BN26 (L26) rat is a congenic strain derived from the SS rat that develops substantially milder SS hypertension and renal injury. 26, 27, 40 MiR-192-5p levels were significantly lower in the renal cortex of SS rats on the LS diet compared with those in the less SS L26 strain (Figure 2A ). MiR-192-5p decreased significantly in both strains in response to the HS diet. However, the level of miR-192-5p remained significantly lower in SS rats than in L26 rats on the HS diet.
Intrarenal artery injection was used subsequently to deliver either locked nucleic acid anti-miR-192-5p or scrambled anti-miR specifically into the left kidney of L26 rats that had undergone a right nephrectomy procedure. Right nephrectomy was performed to prevent compensation from the right kidney as it was not feasible to inject anti-miR into both kidneys. The level of miR-192-5p detectable by quantitative PCR was significantly lower in the renal cortex 5 days after the intrarenal artery delivery of anti-miR-192-5p ( Figure 2B ). The level of miR-192-5p tended to decrease in the renal outer medulla, but the difference was not statistically significant. It is possible that the anti-miR delivered through the renal artery injection did not reach the medulla efficiently. The anti-miR treatment did not affect the level of miR-192-5p in the liver and colon ( Figure 2B ). The liver and colon were chosen for testing because they are among the major sites of miR-192-5p expression outside the kidney. Kidney-specific knockdown is important to test the functional role of renal miR-192-5p, particularly because miR-192-5p is abundant in the gastrointestinal tract where sodium absorption occurs.
Mean arterial BP (MAP) of L26 rats treated with antimiR-192-5p reached 152±5 mm Hg at day 14 after the antimiR treatment and the initiation of the HS diet, which was significantly higher than that of L26 rats treated with a control anti-miR and HS (136±5 mm Hg, n=8 and 6; P<0.05). The HS-induced increases in MAP in the anti-miR-192-5p-treated L26 rats and the scrambled anti-miR-treated rats were 35 and 22 mm Hg, respectively. The effect on BP was observed for both systolic BP (SBP) and diastolic BP (DBP; Figure 2C ).
Kidneys were collected at the end of the study for histological analysis. Trichrome staining did not show any significant difference in glomerulosclerosis or tubulointerstitial fibrosis, although there was a trend for greater injury in the anti-miR-192-5p treated group ( Figure S1 ). Tubular protein casts analysis on slides with hematoxylin and eosin staining showed that the rats treated with anti-miR-192-5p tended to have an increased amount of tubular protein casts (P=0.055), suggesting increased kidney damage ( Figure 2D ).
Mir192 Knockout Exacerbates Angiotensin IIInduced Hypertension in Mice
Mir192 knockout mice were created on the 129S1/SvlmJ mouse background. 19 WT 129S1/SvlmJ mice obtained from Jackson Laboratories were used as controls. The knockout was confirmed by quantitative PCR analysis of miR-192-5p ( Figure 3A) . MAP tended to increase slightly in both WT and knockout mice in response to the HS diet ( Figure 3B ). DBP was significantly higher in the knockout mice compared with the WT mice by the end of the 14-day HS treatment (Figure 3C ). The mice were challenged further for another 14 days with Ang II (angiotensin II; 1 µg/kg per minute given via osmotic minipump) in addition to the HS diet. The Ang II treatment increased the SBP and DBP immediately in both strains. The increase was significantly greater in the knockout mice on the first day that recording was resumed ( Figure 3C) ; however, there was no difference between the 2 strains by the second day. The knockout mice experienced a further elevation of MAP and SBP during the final week of recording that resulted in a significantly higher MAP compared with WT mice at the end of the study (183±3 versus 161±7 mm Hg; n=5 WT and 9 knockout; P<0.05; Figure 3B ). The SBP also was significantly higher in the knockout mice than in the WT in the last 3 days of treatment, whereas the difference in DBP between the 2 strains was not statistically significant ( Figure 3C) .
Kidneys collected at the end of the study did not show significant differences in fibrosis. However, protein casts in the Mir192 knockout were increased significantly compared with those in the WT ( Figure 3D ). These results were consistent with the results of L26 rats treated with anti-miR-192-5p and suggested that reduced levels of miR-192 exacerbate hypertension and renal damage. Table S4 in Liu et al 22 and the text for the characteristics of the patients and biopsy specimens. N=10 control subjects, 8 hypertension, and 32 hypertensive nephrosclerosis; *P<0.05 vs control subjects.
Targeting Atp1b1 Contributes to miR-192-5p's Effect on BP
Atp1b1 mRNA is a confirmed target gene for miR-192-5p. 24 We have reported above that SS rats have reduced levels of miR-192-5p in the renal cortex compared with L26 rats (Figure 2A) . Western blot analysis of the same tissues showed a significantly higher level of ATP1B1 in SS rats compared with that in L26 rats ( Figure 4A ).
ATP1B1 is required for Na + /K + -ATPase activity, which provides the driving force for renal tubular reabsorption. Na + /K + -ATPase activity was measured in the renal cortex of L26 rats treated with intrarenal injection of either anti-miR-192-5p or scrambled anti-miR and in Mir192 knockout and WT mice at the end of the BP experiment shown in Figure 3 . Na + /K + -ATPase activity was significantly higher in L26 rats with miR-192-5p knockdown and in Mir192 knockout mice ( Figure 4B ). Finally, we performed a restoration experiment in which we treated L26 rats with a double intrarenal artery injection of anti-miR-192-5p and either anti-Atp1b1 GapmeR or control GapmeR. We tested the efficacy of the GapmeR alone without anti-miR-192-5p first. Anti-Atp1b1 GapmeR reduced the protein level of ATP1B1 in the renal cortex ( Figure 4C ). The restoration experiment with the double intrarenal artery injection showed that rats treated with anti-Atp1b1 GapmeR had reduced Na + /K + -ATPase activity ( Figure 4D ) and exhibited a blunted BP elevation ( Figure 4E ) compared with those treated with a control GapmeR, all of which were treated with anti-miR-192-5p. After 14 days of HS, the MAP was 157±9 mm Hg in the group treated with anti-miR-192-5p and the control GapmeR compared with 132±8 mm Hg in the group treated with antimiR-192-5p and anti-Atp1b1 GapmeR. Significant differences in MAP also were observed on the second day postinjection. The BP effect was observed for both SBP and DBP ( Figure 4E ). Changes in body weight during the treatment period and tubular cast area at the end of the experiment were not significantly different between the 2 groups ( Figures S2 and S3 ).
Discussion
The findings of the present study suggest that miR-192, particularly miR-192-5p in the kidney, protects against the development of hypertension, which is mediated, at least in part, by suppressing ATP1B1.
MiR-192 is most abundant in the gastrointestinal tract, with the greatest expression in the colon. Other components of the digestive system, including the liver, also express significant levels of miR-192. Outside the digestive system, the kidney is the only organ with a substantial expression of miR-192. 41 MiR-192 is profibrotic in glomeruli and acts as a downstream mediator of TGF (transforming growth factor)-β/ Smad3 (Smad family member 3) signaling, 17, 19, 42 and a reduction in miR-192 leads to decreased proteinuria. 18 In severe diabetic nephropathy, the loss of miR-192 is associated with increased tubulointerstitial fibrosis and decreased estimated glomerular filtration rate. 43 A potassium load, sodium depletion, or aldosterone infusion each reduces miR-192 expression in the kidney significantly, although it is unclear whether miR-192 plays a functional role in the physiological response to these stimuli. 44 We found previously that knocking down miR-192-5p in mice by intraperitoneal injection of locked nucleic acid-modified anti-miR oligonucleotides resulted in an increased expression of ATP1B1 and a blunted adaptive increase of urine output in response to HS diet. 24 The findings of the present study advance this area of research significantly by demonstrating an antihypertensive effect of miR-192 in 2 models of hypertension. The beneficial effect of miR-192-5p in attenuating hypertension and the injurious effect of miR-192-5p in promoting glomerular sclerosis in diabetes mellitus suggest the role of miR-192-5p in the kidney might be tissue-specific. In renal tubules, where miR-192-5p is particularly abundant, its beneficial effect might outweigh any injurious effect it might have. We do not have time course data to know whether tubular cast or hypertension occurs first after miR-192 inhibition or genetic deletion in the present study. However, it is well-established that hypertension, and high renal perfusion pressure specifically, exacerbates renal injury substantially in the SS rat, from which the SS.13 BN26 rat was derived. In addition, our data indicate the hypertensive effect of miR-192-5p inhibition is mediated at least in part by elevation of ATP1B1.
Therefore, it seems that miR-192-5p prevents hypertension with consequent protection against renal tubular injury, although we cannot rule out the possibility that the protection against renal tubular injury contributes to the attenuation of hypertension.
Clinical data support the role of miR-192 in human kidney disease and hypertension. A study of patients with chronic kidney diseases showed an inverse relation between proteinuria and urinary levels of miR-192 and a positive correlation between miR-192 and glomerular filtration rate. 45 Previously, the same group had reported that miR-192 levels were higher in patients with hypertensive nephrosclerosis. However, the kidney biopsies used in that study included complex pathological findings that could confound the interpretation of the data. 46 In our human studies, which excluded kidney specimens with other pathological changes, miR-192-5p was lower in the kidneys of hypertensive nephrosclerosis patients according to agnostic deep sequencing analysis 22 and targeted quantitative PCR analysis in a separate cohort of hypertensive or hypertensive nephrosclerosis patients shown in the present study. Moreover, the gene that encodes miR-192 is 1 of only 6 miRNA genes that show differential expression in human kidney biopsies with hypertensive nephrosclerosis and are located in genomic proximity (within 1 Mb) with BP-associated single nucleotide polymorphisms. 22 The kidney-specific double knockdown experiment presented in the present study demonstrated an important role of Atp1b1 targeting in mediating the effect of renal miR-192-5p on hypertension. The Na + /K + -ATPase is a transmembrane ion transporter found in all cells and is composed of a catalytic α subunit, a β subunit that helps deliver and stabilize the α subunit in the cell membrane, and a tissue-specific auxiliary regulatory subunit. ATP1B1, the β1 subunit of the Na + /K + -ATPase, is necessary not only for the function of the α subunit but also is the limiting factor in the formation of the active heterodimer. 47, 48 Reduced expression of miR-192-5p leads to an increase in Na + /K + -ATPase function, which could, in turn, contribute to hypertension and kidney injury.
We observed an inverse relation between the levels of miR-192-5p and ATP1B1 or Na + /K + -ATPase activities in multiple settings in the present study, consistent with the targeting and suppression of Atp1b1 by miR-192-5p. However, this inverse relation was not observed in all conditions. For example, a high-salt diet decreased miR-192-5p, but ATP1B1 was not elevated under high-salt conditions. Renal Na + /K + -ATPase is essential to drive tubular transport and is regulated strongly by many mechanisms, including those of angiotensin, aldosterone, atrial natriuretic peptide, and dopamine. 49 The way miR-192 is integrated with these other mechanisms to regulate and fine-tune Na + /K + -ATPase activities remains to be studied. The presence of such integrated and potentially redundant mechanisms for Na + /K + -ATPase regulation might explain why miR-192-5p and Na 
Perspectives
Of the hundreds of microRNAs expressed in the kidney, miR-192-5p is one of the first microRNAs that have been shown to play a functional role in the development of hypertension. It will be valuable to explore mechanistic roles of other microRNAs in hypertension and their therapeutic potential. Several microRNAs, including miR-192-5p, are differentially expressed in patients with hypertension and located in genomic proximity with DNA sequence variants associated with BP variation in humans. 22 Another 2 of these microRNAs, miR-214-3p and miR-29, have recently been shown to be involved in the development of hypertension. 22, 50 
